The anti-tumorigenic potential of alternate lymphocytic populations is also supported by a study, which expanded and differentiated glioma patient T cells (of mixed CD3+CD4−CD8−, CD4+, and CD8+ subsets) ex vivo using IL-2, IL-15, and IL-21. The gene discussed is CD4; the disease is glioma.